Showing results (61-70 of 203) with videos related to
Sort By:
Pageof 21
The Journal of Laboratory and Clinical Medicine|May 1, 1983
Urinary excretion of modified nucleosides in chronic myelogenous leukemiaD A Heldman, M R Grever, C E Speicher, et al.Proceedings of the National Academy of Sciences of the United States of America|January 15, 1991
Queuine, a tRNA anticodon wobble base, maintains the proliferative and pluripotent potential of HL-60 cells in the presence of the differentiating agent 6-thioguanineB T French, D E Patrick, M R Grever, et al.American Journal of Hematology|November 1, 1991
Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapyJ L Grem, S A King, H G Chun, et al.Journal of the National Cancer Institute|August 1, 1983
Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemiaD A Heldman, M R Grever, J S Miser, et al.Journal of Interferon Research|October 1, 1990
Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cellsP L Triozzi, K A Avery, M R Grever, et al.Clinical Pharmacology and Therapeutics|December 1, 1983
Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinolS Zimm, J M Collins, D O'Neill, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
Differential effect of 6-ethylmercaptopurine on c-myc expression in wild-type and HGPRT-deficient HL-60 cellsB T French, D E Patrick, M R Grever, et al.Seminars in Oncology|March 3, 1998
Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goalsJ C Byrd, K R Rai, E A Sausville, et al.Journal of the National Cancer Institute|February 1, 1982
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injectionC Erlichman, R C Donehower, J L Speyer, et al.Seminars in Oncology|October 26, 2000
Novel therapies for chronic lymphocytic leukemia in the 21st centuryJ C Byrd, J K Waselenko, M Keating, et al.Pageof 21